| Paclitaxel studied in …STUDIED_INderived10 of 2,325show all (up to 200) |
|---|
| → studied in | NCT03734029Phase 3 · completed Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] · 2,325 trials list this drug (526 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 2,325 trials list this drug (526 active) | — | — | Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · 2,325 trials list this drug (526 active) | — | — | Endometrial Carcinoma,Endometrial Endometrioid Adenocarcinoma,Endometrial Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 2,325 trials list this drug (526 active) | — | — | Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 2,325 trials list this drug (526 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · 2,325 trials list this drug (526 active) | — | — | Neoplasm,Solid Neoplasm,Adult Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06619236Phase 3 · active not recruiting Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer · 2,325 trials list this drug (526 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06623422Phase 3 · recruiting A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694454Phase 1/Phase 2 · suspended Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) · 2,325 trials list this drug (526 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788912Phase 2 · active not recruiting Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) · 2,325 trials list this drug (526 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |